Transforming Sanofi-Aventis


IBS CDC IBS CDC IBS CDC IBS CDC RSS Feed
 
Case Studies | Cases in Business, Management, Cases | Case Study

ICMR HOME | Case Studies Collection

Case Details:

Case Code : BSTR358
Case Length : 18 Pages
Period : 2008-2009
Pub Date : 2010
Teaching Note :Not Available
Organization : Sanofi-Aventis
Industry : Healthcare / Pharmaceuticals
Countries : France; Global

To download Transforming Sanofi-Aventis case study (Case Code: BSTR358) click on the button below, and select the case from the list of available cases:





Price:

For delivery in electronic format: Rs. 300;
For delivery through courier (within India): Rs. 300 + Rs. 25 for Shipping & Handling Charges

Business Strategy Case Studies
Case Studies Collection
Business Strategy Short Case Studies
View Detailed Pricing Info
How To Order This Case
Business Case Studies
Area Specific Case Studies
Industry Wise Case Studies
Company Wise Case Studies



Please note:

This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source.

<< Previous

Introduction Contd...

It reported sales of €27,438 million for Q2 2009 as compared to €6,689 million for the corresponding period of 2008.3 Its stocks had also grown faster than that of its peer group - a complete reversal of fortunes for a company whose stocks had been considered the worst performing of its peer group barely a year earlier (Refer to Exhibit I for Sanofi-Aventis' consolidated income statement for the first half of 2009; and, Exhibit II for its five-year stock chart).

However, analysts also felt that, going forward, Viehbacher was likely to come up against many tough challenges. The Paris-based Sanofi-Aventis was the world's third largest pharmaceutical company as of 2009.

However, experts felt that it had a costly and unproductive research and development (R&D) pipeline, with few new products in sight to offset the impact of patent expiries of its top-selling drugs between 2009 and 2013...

Excerpts >>


2] As of August 2009, €1 approximately equals US$1.45.

3] "Very Good Second Quarter 2009 Increase in 2009 Guidance," http://en.sanofi-aventis.com, July 29, 2009.


Case Studies Links:- Case Studies, Short Case Studies, Simplified Case Studies.

Other Case Studies:- Multimedia Case Studies, Cases in Other Languages.

Business Reports Link:- Business Reports.

Books:- Textbooks, Work Books, Case Study Volumes.